Celon Pharma Sa · GPW:CLN

Celon Pharma Sa — H1 2024 Earnings Presentation

13 slides from Celon Pharma Sa's earnings presentation, Sep 19, 2024

  1. Slide 1: Investor Presentation Q2 2024 / 1H 2024 results

    INVESTOR PRESENTATION Q22024/1H2024 results WARSAW // 19.09.2024

  2. Slide 2: Disclaimer

    Neither this presentation (the “Presentation”, references to which shall be deemed to include any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) nor any copy of it nor the information contained herein is being is

  3. Slide 3: Pharma Financials

    PHARMA FINANCIALS

  4. Slide 4: Generics

    Generics Q1-2024 Q1-2023 Q2-2024 Q2-2023 H1-2024 H1-2023 Change Change Change All amounts in kPLN Actual Actual Actual Actual Actual Actual Q1'24 / Q1'23 Q2'24 / Q2'23 H1'24 / H1'23 Revenues 36 318 39 314 53 572 43 215 89 889 82 529 -8% 24% 9% Revenues from sales of medicines 34 798 39 006 53 582 42

  5. Slide 5: R&D

    R&D Q1-2024 Q1-2023 Q2-2024 Q2-2023 H1-2024 H1-2023 Change Change Change All amounts in kPLN Actual Actual Actual Actual Actual Actual Q1'24 / Q1'23 Q2'24 / Q2'23 H1'24 / H1'23 Revenues 4 016 4 577 12 041 25 737 16 056 30 314 -12% -53% -47% Revenues from sales of medicines - - - - - - 0% 0% 0% Other

  6. Slide 6: All segments

    All segments Q1-2024 Q1-2023 Q2-2024 Q2-2023 H1-2024 H1-2023 Change Change Change All amounts in kPLN Actual Actual Actual Actual Actual Actual Q1'24 / Q1'23 Q2'24 / Q2'23 H1'24 / H1'23 Revenues 40 334 43 891 65 613 68 952 105 945 112 843 -8% -5% -6% Revenues from sales of medicines 34 798 39 006 53

  7. Slide 7: Balance sheet

    Balance sheet. PLN mln 30.06.2024 31 .12..2023 ASSETS 575,5 569,3 Non-current assets 368,8 379,6 A. The decrease in fixed assets as of June 30, 2024, compared to Property, plant and equipment A 287,1 298,9 Right-of-use assets 35,9 34,9 December 31, 2023, is related to the intensive capital expenditu

  8. Slide 8: Branded Generics

    PHARMA BRANDED GENERICS

  9. Slide 9: Zarixa - successful product launch - strengthening Company's generic portfolio

    Zarixa - successful product launch - strengthening Company's generic portfolio Salmex Zarixa Ketrel Valzek Donepex 18 000 16 000 14 000 12 000 Sales (PLN, 000) 10 000 8 000 6 000 4 000 2 000 0 08/23 09/23 10/23 11/23 12/23 01/24 02/24 03/24 04/24 05/24 06/24 07/24 08/24 Salmex 5 689 6 557 6 648 6 96

  10. Slide 10: Rivaroxaban - brands share - gross sales value

    Rivaroxaban - brands share - gross sales value 9,00% 8,00% 7,00% 6,00% 5,00% 4,00% 3,00% 2,00% 1,00% 0,00% 02.06.2024 09.06.2024 16.06.2024 23.06.2024 30.06.2024 07.07.2024 14.07.2024 21.07.2024 28.07.2024 04.08.2024 11.08.2024 18.08.2024 25.08.2024 01.09.2024 08.09.2024 ZARIXA XILTESS XANIRVA RIXAC

  11. Slide 11: Innovative Business

    PHARMA ININIOW NENA BUSINESS

  12. Slide 12: Neuropsychiatry clinical pipeline - Key Milestones & Partnering 2024/2025

    Clinical pipeline - Key Milestones & Partnering 2024/2025 Molecular Program Phase 1 Phase 2 Milestone Partnering status Target Neuropsychiatry NMDAR Agonist Falkieri Esketamine Treatment-Resistant Depression Ready to start Phase 3 Tang Capital LPP/Novohale Schizophrenia Phase 2 data completed CPL’36

  13. Slide 13: QA

    QA

Celon Pharma — H1 2024 Earnings Presentation on 6ix